CTOs on the Move

biOasis Technologies Inc

www.bioasis.ca

 
biOasis Technologies Inc., an early stage biopharmaceutical company, engages in the research, development, and commercialization of technologies and products for the diagnosis and treatment of central nervous system diseases and disorders. The company develops Transcend program, a protein vector, which is a proprietary carrier for the transport of therapeutic agents across the blood brain barrier for treatment of a range of neurological, oncological, and infectious disease applications; and Cognitest, a proprietary in vitro diagnostic assay for Alzheimer’s disease. It has a collaborative research agreement with the University of British Columbia to assist the company in development of an enzyme linked ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bioasis.ca
  • 3489 Canterbury Pl
    Surrey, BC CAN V3S 0G8
  • Phone: 604.542.5059

Executives

Name Title Contact Details

Similar Companies

Alamar Biosciences

Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.

ChemNavigator

ChemNavigator is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

chemill Inc

chemill Inc is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intellikine

Intellikine is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Goldfinch Bio

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.